Free Trial
Eva Fortea-Verdejo

Eva Fortea-Verdejo Analyst Performance

Biotech equity research analyst at Wells Fargo & Company

Eva Fortea-Verdejo is a stock analyst at Wells Fargo & Company in the medical sector, covering 1 publicly traded companies. Over the past year, Eva Fortea-Verdejo has issued 2 stock ratings, including and hold recommendations. While full access to Eva Fortea-Verdejo's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eva Fortea-Verdejo's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
2 Last 0 Years
Buy Recommendations
0.00% 0 Buy Ratings
Companies Covered
1 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy0.0%0 ratings
Hold100.0%2 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Hold recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
1 company

Eva Fortea-Verdejo, an analyst at Wells Fargo & Company, currently covers 1 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
1 company
100.0%

Eva Fortea-Verdejo of Wells Fargo & Company specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
1 company
100.0%

Eva Fortea-Verdejo's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Merus N.V. stock logo
MRUS
Merus
9/29/2025Reiterated Rating$94.15$97.00Equal Weight
Merus N.V. stock logo
MRUS
Merus
9/29/2025Downgrade$93.67$97.00Equal Weight